BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, June 17, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» New α1-antitrypsin correctors disclosed in Sub21 patent
To read the full story,
subscribe
or
sign in
.
Endocrine/metabolic
New α1-antitrypsin correctors disclosed in Sub21 patent
May 29, 2025
Sub21 Inc. has divulged α1-antitrypsin (SERPINA1) (Z-mutant) correctors reported to be useful for the treatment of α1-antitrypsin deficiency.
BioWorld Science
Endocrine/metabolic
Patents
